Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P10415
UPID:
BCL2_HUMAN
Alternative names:
-
Alternative UPACC:
P10415; C9JHD5; P10416; Q13842; Q16197
Background:
Apoptosis regulator Bcl-2 plays a pivotal role in cell survival, regulating mitochondrial membrane permeability and inhibiting caspase activity, thus suppressing apoptosis in various cell systems. It also acts as an autophagy inhibitor by interacting with BECN1 and AMBRA1, and may reduce inflammation by impairing NLRP1-inflammasome activation.
Therapeutic significance:
Understanding the role of Apoptosis regulator Bcl-2 could open doors to potential therapeutic strategies, especially in diseases where apoptosis and autophagy play critical roles.